Edap Tms (NASDAQ:EDAP)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Tuesday.
EDAP has been the topic of several other research reports. ValuEngine cut Edap Tms from a “buy” rating to a “hold” rating in a research report on Saturday, June 16th. TheStreet raised Edap Tms from a “d+” rating to a “c” rating in a research report on Tuesday, June 26th.
EDAP stock opened at $2.94 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.04 and a current ratio of 2.45. Edap Tms has a 1-year low of $2.07 and a 1-year high of $4.25. The firm has a market capitalization of $87.28 million, a price-to-earnings ratio of -294.00 and a beta of 0.52.
Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings data on Wednesday, August 29th. The medical equipment provider reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). Edap Tms had a negative return on equity of 4.04% and a negative net margin of 3.55%. The business had revenue of $10.14 million during the quarter, compared to analysts’ expectations of $10.74 million. research analysts predict that Edap Tms will post -0.01 earnings per share for the current year.
An institutional investor recently raised its position in Edap Tms stock. Archon Capital Management LLC boosted its holdings in Edap Tms SA (NASDAQ:EDAP) by 7.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,019,011 shares of the medical equipment provider’s stock after purchasing an additional 71,336 shares during the period. Edap Tms comprises 0.2% of Archon Capital Management LLC’s holdings, making the stock its 14th largest position. Archon Capital Management LLC owned approximately 3.51% of Edap Tms worth $2,364,000 as of its most recent SEC filing. 8.13% of the stock is owned by institutional investors and hedge funds.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Recommended Story: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.